There is just so much information coming out in the newspapers today about all of the different kinds of scientific successes using adult stem cells. And from the San Jose Mercury News,

“Many of the technologies we hyped to the general public haven’t worked
yet,” Celgene President Alan Lewis said Wednesday at a biotechnology trade show
in Philadelphia. He also noted that venture capitalists “are very cautious”
about investing in stem-cell companies because of uncertainty over the field’s
future.

Geron, the money-losing Menlo Park biotechnology company, for example, has
poured $100 million into human embryonic stem-cell research since 1996 — about
twice the amount the U.S. government has committed. Geron is by far the
largest company in the field, and it lost about $80 million last year.”

Author Profile

Jennifer Lahl, CBC President
Jennifer Lahl, CBC President
Jennifer Lahl is founder and president of The Center for Bioethics and Culture Network. Lahl couples her 25 years of experience as a pediatric critical care nurse, a hospital administrator, and a senior-level nursing manager with a deep passion to speak for those who have no voice. Lahl’s writings have appeared in various publications including Cambridge University Press, the San Francisco Chronicle, the Dallas Morning News, and the American Journal of Bioethics. As a field expert, she is routinely interviewed on radio and television including ABC, CBS, PBS, and NPR. She is also called upon to speak alongside lawmakers and members of the scientific community, even being invited to speak to members of the European Parliament in Brussels to address issues of egg trafficking; she has three times addressed the United Nations during the Commission on the Status of Women on egg and womb trafficking.